Abstract:N‐glycosylation is a common protein modification at the cell surface and known to regulate many processes including cell–cell interactions. N‐glycans are processed through a highly choreographed pathway that occurs during cell secretion, though the role of different N‐glycoforms in natural killer cell function is unexplored. Rodriguez Benavente et al explore the impact of NK cell N‐glycan processing on an antibody‐dependent immune response, antibody binding affinity, and structure of the antibody‐binding receptor, CD16a, at the surface and found marked changes in all three characteristics. Thus, NK cell N‐glycan processing represents an unexplored attribute that regulates an immune response. Novel approaches are required to improve the efficacy of immunotherapies and increase the proportion of patients who experience a benefit. Antibody‐dependent cell‐mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies. Natural killer (NK) cells mediate ADCC, though responses are highly variable and depend on prior treatment as well as other factors. Thus, strategies to increase NK cell activity are expected to improve multiple therapies. Both cytokine treatment and NK cell receptor engineering are being explored to increase ADCC. Post‐translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC. We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine‐linked (N‐)glycan processing, on ADCC using primary and cultured human NK cells. We also probed affinity using binding assays and CD16a structure with nuclear magnetic resonance spectroscopy. Treating primary human NK cells and cultured YTS‐CD16a cells with kifunensine doubled ADCC in a CD16a‐dependent manner. Kifunensine treatment also increased the antibody‐binding affinity of CD16a on the NK cell surface. Structural interrogation identified a single CD16a region, proximal to the N162 glycan and the antibody‐binding interface, perturbed by the N‐glycan composition. The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%. These results demonstrate native N‐glycan processing is an important factor that limits NK cell ADCC. Furthermore, optimal antibody and CD16a glycoforms are defined that provide the greatest ADCC activity.

One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa/CD16a structure

One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa / CD16a structure

Effects of Anchor Structure and Glycosylation of Fcγ Receptor III on Ligand Binding Affinity.

Inhibiting N‐glycan processing increases the antibody binding affinity and effector function of human natural killer cells

Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC

The FcγRIIIA (CD16) L48-H/R polymorphism enhances NK cell-mediated antibody-dependent cellular cytotoxicity by promoting serial killing

The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding

Fc-Dependent Expression Of Cd137 On Human Nk Cells: Insights Into "Agonistic" Effects Of Anti-Cd137 Monoclonal Antibodies

Regulation of Natural Killer cell cytotoxicity by shedding of the Fc receptor CD16

Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes.

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for FCGR3

Characterization of Endogenous Human FcγRIII by Mass Spectrometry Reveals Site, Allele and Sequence Specific Glycosylation*

Re-evaluation of the involvement of NK cells and C-type lectin-like NK receptors in modulation of immune responses by multivalent GlcNAc-terminated oligosaccharides

Influence of glycan modification on IgG1 biochemical and biophysical properties

Correlation of N-glycan Dynamics and Interaction Network with Allosteric Antigen Binding and Fc Receptor Recognition

An atomistic perspective on ADCC quenching by core-fucosylation of IgG1 Fc N-glycans from enhanced sampling molecular dynamics

Regulation of Activated Cd4(+) T Cells by Nk Cells Via the Qa-1-Nkg2a Inhibitory Pathway

Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells

Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes

Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies